A XM não fornece serviços a residentes nos Estados Unidos da América.
P
P

Pfizer


Notícias

FDA authorizes Novavax's updated COVID vaccine targeting JN.1 strain

UPDATE 4-FDA authorizes Novavax's updated COVID vaccine targeting JN.1 strain Updates shares, adds company comment in paragraph 6 By Sriparna Roy Aug 30 (Reuters) - The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax's NVAX.O COVID shot. The updated vaccine is authorized for use in individuals 12 years of age and older and will target the JN.1 strain of the virus.
P

What to Watch in the Weak Ahead and on Tuesday, September 3

What to Watch in the Weak Ahead and on Tuesday, September 3 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON TUESDAY On the U.S. economic calendar, S&P Global's final reading of manufacturing Purchasing Managers' Index (PMI) for August is slated for release.
G
P
D

Alnylam shares slide after heart drug data fails to impress investors

Alnylam shares slide after heart drug data fails to impress investors Aug 30 (Reuters) - Alnylam Pharmaceuticals' ALNY.O shares fell nearly 11% before the bell on Friday, after data for its closely watched heart drug fell short of heightened investor expectations. The company's shares have climbed more than 70% since it disclosed early results of the late-stage study of the drug, vutrisiran , in June.
P

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits

UPDATE 3-Delaware top court will hear drugmakers' appeal to end Zantac lawsuits Adds response from plaintiffs' attorneys in paragraph 5 By Brendan Pierson Aug 27 (Reuters) - Delaware's highest court said on Tuesday it will hear an appeal by GSK GSK.L and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer.
G
P
S

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits Aug 27 (Reuters) - Delaware's highest court said on Tuesday it will hear an appeal by GSK GSK.L and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer. GSK, Pfizer PFE.N , Sanofi SASY.PA and Boehringer Ingelheim are asking the court to overturn an order by a lower court judge allowing plaintiffs in the lawsuits to offer expert testimony on the alleged cancer lin
G
P
S

Hims & Hers Health falls after Lilly launches single-dose vials of weight-loss drug

BUZZ-Hims & Hers Health falls after Lilly launches single-dose vials of weight-loss drug ** Shares of telehealth company Hims & Hers Health HIMS.N fall 5% to $15.25 premarket ** Eli Lilly LLY.N says it has begun selling single-dose vials of its popular weight-loss drug Zepbound in the U.S. through its LillyDirect website ** The 2.5 milligram and 5
P

Pfizer Launches Pfizerforall™, A Digital Platform That Helps Simplify Access To Healthcare

BRIEF-Pfizer Launches Pfizerforall™, A Digital Platform That Helps Simplify Access To Healthcare Aug 27 (Reuters) - Pfizer Inc PFE.N : PFIZER LAUNCHES PFIZERFORALL™, A DIGITAL PLATFORM THAT HELPS SIMPLIFY ACCESS TO HEALTHCARE PFIZER INC - PFIZERFORALL DESIGNED FOR MIGRAINE, COVID-19, FLU PATIENTS PFIZER INC - PFIZERFORALL OFFERS HOME DELIVERY OF MEDICINES PFIZER: WORKING WITHIN EXISTING U.S.
P

Pfizer launches new website for migraine, respiratory offerings

Pfizer launches new website for migraine, respiratory offerings By Michael Erman Aug 27 (Reuters) - Pfizer Inc PFE.N is launching a new website to promote and improve access to its health care offerings for migraine and respiratory illnesses. The drugmaker said on Tuesday that it launched the site called PfizerForAll to help patients get access to treatments like its COVID-19 drug Paxlovid and its migraine pill Nurtec by offering services like telehealth appointments and diagnostic tests.
P

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year By Patrick Wingrove Aug 26 (Reuters) - Cigna CI.N said on Monday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey biosimilar versions of the medicine instead.
A
C
P
T

US CDC To Reopen Free At Home, Covid 19 Test Delivery Programs In Late September

BRIEF-US CDC To Reopen Free At Home, Covid 19 Test Delivery Programs In Late September Aug 23 (Reuters) - US CDC SAYS FREE AT HOME, COVID 19 TEST DELIVERY PROGRAMS WILL REOPEN IN LATE SEPTEMBER -PRESS CONFERENCE US HHS SAYS HAS LAUNCHED NEW NATIONAL CAMPAIGN TO EDUCATE AUDIENCES AT HIGH RISKS OF FLU, COVID, 19 AND RSV -PRESS CONFERENCE US CDC SAYS
P

US to offer free COVID tests in September as part of fall campaign

UPDATE 2-US to offer free COVID tests in September as part of fall campaign Adds details on testing program in paragraph 2, background on COVID infections in paragraph 5, details from press briefing throughout By Manas Mishra and Julie Steenhuysen Aug 23 (Reuters) - The U.S. government will provide free COVID-19 tests by mail starting in late September, as it kicks off a fall campaign urging eligible Americans to get vaccinated against COVID, flu and RSV, health officials said on Friday.
P

Ozempic on Wall Street's list for 2027 Medicare drug negotiations

ANALYSIS-Ozempic on Wall Street's list for 2027 Medicare drug negotiations Novo Nordisk, Pfizer, GSK drugs likely to be in 2027 Medicare negotiations Most drugs already discounted, limited impact seen on Big Pharma Analysts expect price cuts to have bigger bite starting in 2028 By Michael Erman NEW YORK, Aug 23 (Reuters) - Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026 , Wall Street analysts are betting on a 2027 list that will include Novo N
G
P
T

Pfizer- Shipping For Pfizer & Biontech 2024-2025 Covid-19 Vaccine To Begin Shipping Immediately

BRIEF-Pfizer- Shipping For Pfizer & Biontech 2024-2025 Covid-19 Vaccine To Begin Shipping Immediately Aug 22 (Reuters) - Pfizer: PFIZER- SHIPPING FOR PFIZER & BIONTECH 2024-2025 COVID-19 VACCINE TO BEGIN SHIPPING IMMEDIATELY PFIZER- PFIZER & BIONTECH 2024-2025 COVID-19 VACCINE TO BE AVAILABLE ACROSS U.S. BEGINNING IN COMING DAYS
P

US FDA approves updated COVID shots ahead of fall and winter

UPDATE 4-US FDA approves updated COVID shots ahead of fall and winter Adds Novavax response in paragraph 11 By Mariam Sunny and Manas Mishra Aug 22 (Reuters) - The U.S. Food and Drug Administration on Thursday approved updated COVID-19 vaccines made by Pfizer PFE.N and Moderna MRNA.O targeting a recent variant of the disease, in time for a fall vaccination campaign.
P

FDA Approves And Authorizes Updated mRNA Covid-19 Vaccines To Better Protect Against Currently Circulating Variants

BRIEF-FDA Approves And Authorizes Updated mRNA Covid-19 Vaccines To Better Protect Against Currently Circulating Variants Aug 22 (Reuters) - U.S. FDA: FDA APPROVES AND AUTHORIZES UPDATED MRNA COVID-19 VACCINES TO BETTER PROTECT AGAINST CURRENTLY CIRCULATING VARIANTS US FDA: UPDATED MRNA COVID-19 VACCINES INCLUDE COMIRNATY AND SPIKEVAX, BOTH OF WHIC
P

US FDA approves updated COVID shots ahead of fall season

US FDA approves updated COVID shots ahead of fall season Aug 22 (Reuters) - The U.S. Food and Drug Administration has approved updated COVID-19 vaccines made by Pfizer PFE.N and Moderna MRNA.O targeting newer variants of the disease in time for a fall vaccination campaign, the agency said on Thursday. The regulator has approved the vaccines to target a variant known as "KP.2", which dominated infections in recent months, for individuals aged 12 years and above.
P

FDA Says Infants At Risk For Aluminum Toxicity With Unapproved Potassium Phosphates Drug Product

BRIEF-FDA Says Infants At Risk For Aluminum Toxicity With Unapproved Potassium Phosphates Drug Product Aug 21 (Reuters) - FDA: FDA: INFANTS AT RISK FOR ALUMINUM TOXICITY WITH UNAPPROVED POTASSIUM PHOSPHATES DRUG PRODUCT FDA: AWARE THAT SOME HOSPITALS CONTINUE TO BUY HOSPIRA’S UNAPPROVED POTASSIUM PHOSPHATES PRODUCT TO USE IN CHILDREN FDA: ON AUG
P

U.S. STOCKS B Riley, Energy stocks, Pharma stocks

BUZZ-U.S. STOCKS ON THE MOVE-B Riley, Energy stocks, Pharma stocks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 paused on Friday as investors digested a spate of encouraging economic data that dispelled slowdown concerns and put Wall Street's main indexes on course for their best weekly performance this year.
C
M
P
T
T
U
U
U

U.S. STOCKS Pharma stocks, H & R Block, B Riley Financial

REFILE-BUZZ-U.S. STOCKS ON THE MOVE-Pharma stocks, H & R Block, B Riley Financial Adds dropped names in headline Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes slipped on Friday following the S&P 500 and the Nasdaq's six-day winning streaks after a spate of encouraging economic data allayed recession worries, while weak housing data dampened sentiment.
C
P
T
U
U
U

Pfizer falls as flu-COVID combination shot misses one of the main goals in study

BUZZ-Pfizer falls as flu-COVID combination shot misses one of the main goals in study ** Shares of drugmaker Pfizer PFE.N fall 2.8% to $27.92 ** PFE and BioNTech 22UAy.DE say their experimental combination mRNA vaccine to protect against influenza and COVID-19 failed to meet one of the two main goals in a late-stage study ** Companies say they are
P



Condições

Ativos populares

Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.

Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.

Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.

Aviso de risco: O seu capital está em risco. Os produtos alavancados podem não ser adequados para todos. Recomendamos que consulte a nossa Divulgação de Riscos.